Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.19 USD
Change Today +0.09 / 0.74%
Volume 919.5K
AFFX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFFX) Snapshot

Open
$12.15
Previous Close
$12.10
Day High
$12.21
Day Low
$11.99
52 Week High
03/17/15 - $13.11
52 Week Low
10/15/14 - $7.00
Market Cap
942.6M
Average Volume 10 Days
1.0M
EPS TTM
$0.13
Shares Outstanding
77.3M
EX-Date
--
P/E TM
91.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for AFFYMETRIX INC (AFFX)

affymetrix inc (AFFX) Related Businessweek News

No Related Businessweek News Found

affymetrix inc (AFFX) Details

Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment engages in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line; products with clinical diagnostic and research applications, such as the CytoScan and OncoScan products; GeneTitan instrument system that runs genotyping and gene expression array plates; and QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers and other biological and health care manufacturers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta Plex assays for low to mid-plex experiments. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

1,100 Employees
Last Reported Date: 04/30/15
Founded in 1991

affymetrix inc (AFFX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $549.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $349.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $399.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $349.8K
Compensation as of Fiscal Year 2014.

affymetrix inc (AFFX) Key Developments

Affymetrix Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Affymetrix Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $88,717,000 compared to $82,971,000 a year ago. Income from operations was $7,285,000 compared to loss from operations of $8,742,000 a year ago. Income before income taxes was $5,129,000 compared to loss before income taxes of $10,202,000 a year ago. Net income was $4,386,000 compared to net loss of $10,474,000 a year ago. Basic and diluted net income per share was $0.06 compared to basic and diluted net loss per share of $0.14 a year ago. Basic and diluted Non-GAAP net income was $7,884,000 compared to $1,904,000 a year ago. Basic and diluted Non-GAAP net income per share was $0.10 compared to $0.03 a year ago. EBITDA was $12,145,000 compared to $3,135,000 a year ago. Adjusted EBITDA was $17,132,000 compared to $12,916,000 a year ago. The company generated cash flow of approximately $1.3 million from operating activities.

Affymetrix and EverGene Ltd. Collaborate in Genetic Research and Personal Genomics Services in Japan

Affymetrix and MTI Ltd., through its wholly-owned subsidiary, EverGene Ltd., (MTI/EG) announce that the two companies will collaborate in genetic research and personal genomics services in Japan. With the support of leading academics and through this collaboration, MTI/EG plans to further expand their business in the healthcare field. MTI/EG announced the launch of 'DearGene Starter Kit', which is an updated genotyping service for consumers. This service is a comprehensive genotyping analysis that provides diseases onset risk based on a risk calculation model developed by Dr. Kamatani. Affymetrix’ Axiom genotyping platform will be used for generating the individual’s genotyping data. Affymetrix will support MTI/EG in their genetic research and PGS programs in Japan by supplying its Axiom Genotyping Solution for the highly accurate measurement of genetic variation. Samples from MTI/EG will be processed exclusively by Takara Bio Inc. of Japan, who has a excellent and long established reputation in the genomics field. Affymetrix has begun providing MTI/EG with custom Axiom genotyping arrays for the collaborative research program, and will supply custom Axiom arrays for MTI/EG’s personal genomics service, 'DearGene Starter Kit'.

Affymetrix Inc. to Report Q1, 2015 Results on Apr 29, 2015

Affymetrix Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on Apr 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFFX:US $12.19 USD +0.09

AFFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.61 USD -0.08
Fluidigm Corp $36.60 USD +0.10
Luminex Corp $16.28 USD -0.23
Sequenom Inc $4.47 USD -0.06
Takara Bio Inc ¥1,343 JPY +2.00
View Industry Companies
 

Industry Analysis

AFFX

Industry Average

Valuation AFFX Industry Range
Price/Earnings 82.0x
Price/Sales 2.6x
Price/Book 3.1x
Price/Cash Flow 84.9x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit www.affymetrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.